(ONC) BeiGene - Ratings and Ratios
BTK-Inhibitor, Anti-PD-1, PARP-Inhibitor, Bcl-2-Inhibitor, Bispecific-Antibody
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 47.8% |
| Value at Risk 5%th | 73.6% |
| Relative Tail Risk | -6.34% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.43 |
| Alpha | 77.90 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.445 |
| Beta | 0.494 |
| Beta Downside | 0.927 |
| Drawdowns 3y | |
|---|---|
| Max DD | 52.82% |
| Mean DD | 22.60% |
| Median DD | 23.07% |
Description: ONC BeiGene September 29, 2025
BeOne Medicines AG (formerly BeiGene, Ltd.) is a Basel-based oncology biotech that discovers and develops small-molecule and antibody therapeutics across the United States, China, Europe and other markets. Its commercial portfolio includes BRUKINSA (BTK inhibitor for blood cancers), TEVIMBRA (anti-PD-1 immunotherapy for solid and hematologic tumors) and PARTRUVIX (PARP1/2 inhibitor under evaluation as monotherapy and in combination regimens).
The clinical pipeline spans more than 30 candidates, ranging from Bcl-2 inhibitor Sonrotoclax (BGB-11417) to next-generation BTK degraders (BGB-16673), TIGIT inhibitor Ociperlimab, multiple ADCs (e.g., anti-B7H3, anti-FGFR2b), bispecific antibodies (e.g., Zanidatamab, anti-GPC3x4-1BB) and a pan-KRAS inhibitor (BGB-53038). Pre-clinical programs complement this breadth, positioning BeOne as a diversified oncology platform.
Strategic collaborations with Amgen, BMS, Novartis and others provide co-development funding and market access, while the company’s 2023 financials reported revenue of roughly $2.5 billion, a 12 % YoY increase driven largely by BRUKINSA sales in China. The global BTK inhibitor market is projected to reach $4 billion by 2028 (CAGR ≈ 9 %), and the broader immuno-oncology sector is expected to grow at a 10-12 % annual rate, underscoring the macro-tailwinds behind BeOne’s product mix.
Given the depth of its pipeline and the accelerating demand for targeted and immuno-oncology therapies, a quantitative comparison of BeOne’s valuation multiples against sector peers can help gauge upside potential; the ValueRay platform offers a data-driven dashboard you may find useful for that analysis.
ONC Stock Overview
| Market Cap in USD | 38,652m |
| Sub-Industry | Biotechnology |
| IPO / Inception | 2016-02-03 |
| Return 12m vs S&P 500 | 60.8% |
| Analyst Rating | 4.58 of 5 |
ONC Dividends
Currently no dividends paidONC Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | 26.19% |
| CAGR/Max DD Calmar Ratio | 0.50 |
| CAGR/Mean DD Pain Ratio | 1.16 |
| Current Volume | 209k |
| Average Volume | 230k |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (68.5m TTM) > 0 and > 6% of Revenue (6% = 298.4m TTM) |
| FCFTA 0.06 (>2.0%) and ΔFCFTA 23.94pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 66.28% (prev 56.87%; Δ 9.41pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.10 (>3.0%) and CFO 785.4m > Net Income 68.5m (YES >=105%, WARN >=100%) |
| Net Debt (-3.02b) to EBITDA (301.3m) ratio: -10.01 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.39 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (114.5m) change vs 12m ago 9.38% (target <= -2.0% for YES) |
| Gross Margin 86.19% (prev 83.74%; Δ 2.45pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 73.87% (prev 56.88%; Δ 16.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -10.73 (EBITDA TTM 301.3m / Interest Expense TTM -15.5m) >= 6 (WARN >= 3) |
Altman Z'' -3.13
| (A) 0.43 = (Total Current Assets 5.66b - Total Current Liabilities 2.37b) / Total Assets 7.63b |
| (B) -1.10 = Retained Earnings (Balance) -8.39b / Total Assets 7.63b |
| warn (B) unusual magnitude: -1.10 — check mapping/units |
| (C) 0.02 = EBIT TTM 166.7m / Avg Total Assets 6.73b |
| (D) -2.42 = Book Value of Equity -8.49b / Total Liabilities 3.50b |
| Total Rating: -3.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 63.70
| 1. Piotroski 6.0pt |
| 2. FCF Yield 1.30% |
| 3. FCF Margin 9.34% |
| 4. Debt/Equity 0.25 |
| 5. Debt/Ebitda -10.01 |
| 6. ROIC - WACC (= -4.62)% |
| 7. RoE 1.86% |
| 8. Rev. Trend 96.79% |
| 9. EPS Trend 62.11% |
What is the price of ONC shares?
Over the past week, the price has changed by -5.18%, over one month by +9.64%, over three months by +12.92% and over the past year by +79.81%.
Is ONC a buy, sell or hold?
- Strong Buy: 15
- Buy: 8
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the ONC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 398.5 | 14.1% |
| Analysts Target Price | 398.5 | 14.1% |
| ValueRay Target Price | 382.9 | 9.6% |
ONC Fundamental Data Overview November 21, 2025
P/E Trailing = 659.0378
P/E Forward = 43.8596
P/S = 7.7728
P/B = 9.4723
Beta = 0.464
Revenue TTM = 4.97b USD
EBIT TTM = 166.7m USD
EBITDA TTM = 301.3m USD
Long Term Debt = 139.6m USD (from longTermDebt, last quarter)
Short Term Debt = 829.0m USD (from shortTermDebt, last quarter)
Debt = 1.02b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -3.02b USD (from netDebt column, last quarter)
Enterprise Value = 35.63b USD (38.65b + Debt 1.02b - CCE 4.04b)
Interest Coverage Ratio = -10.73 (Ebit TTM 166.7m / Interest Expense TTM -15.5m)
FCF Yield = 1.30% (FCF TTM 464.6m / Enterprise Value 35.63b)
FCF Margin = 9.34% (FCF TTM 464.6m / Revenue TTM 4.97b)
Net Margin = 1.38% (Net Income TTM 68.5m / Revenue TTM 4.97b)
Gross Margin = 86.19% ((Revenue TTM 4.97b - Cost of Revenue TTM 686.7m) / Revenue TTM)
Gross Margin QoQ = 86.09% (prev 87.49%)
Tobins Q-Ratio = 4.67 (Enterprise Value 35.63b / Total Assets 7.63b)
Interest Expense / Debt = 1.79% (Interest Expense 18.2m / Debt 1.02b)
Taxrate = 15.17% (22.3m / 147.2m)
NOPAT = 141.4m (EBIT 166.7m * (1 - 15.17%))
Current Ratio = 2.39 (Total Current Assets 5.66b / Total Current Liabilities 2.37b)
Debt / Equity = 0.25 (Debt 1.02b / totalStockholderEquity, last quarter 4.13b)
Debt / EBITDA = -10.01 (Net Debt -3.02b / EBITDA 301.3m)
Debt / FCF = -6.49 (Net Debt -3.02b / FCF TTM 464.6m)
Total Stockholder Equity = 3.68b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.90% (Net Income 68.5m / Total Assets 7.63b)
RoE = 1.86% (Net Income TTM 68.5m / Total Stockholder Equity 3.68b)
RoCE = 4.36% (EBIT 166.7m / Capital Employed (Equity 3.68b + L.T.Debt 139.6m))
RoIC = 3.04% (NOPAT 141.4m / Invested Capital 4.65b)
WACC = 7.67% (E(38.65b)/V(39.67b) * Re(7.83%) + D(1.02b)/V(39.67b) * Rd(1.79%) * (1-Tc(0.15)))
Discount Rate = 7.83% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 4.90%
[DCF Debug] Terminal Value 71.59% ; FCFE base≈464.6m ; Y1≈320.9m ; Y5≈162.4m
Fair Price DCF = 30.86 (DCF Value 3.14b / Shares Outstanding 101.8m; 5y FCF grow -36.24% → 3.0% )
EPS Correlation: 62.11 | EPS CAGR: 253.5% | SUE: 0.46 | # QB: 0
Revenue Correlation: 96.79 | Revenue CAGR: 61.17% | SUE: N/A | # QB: 0
Additional Sources for ONC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle